Skip to main content

Drug Interactions between chloramphenicol and Ergamisol

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

chloramphenicol levamisole

Applies to: chloramphenicol and Ergamisol (levamisole)

GENERALLY AVOID: Coadministration of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia, and bone marrow depression) have been reported after short-term and long-term systemic therapy with chloramphenicol.

MANAGEMENT: Concurrent use of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis, such as sulfonamides, nucleoside reverse transcriptase inhibitors, procainamide, phenylbutazone, clozapine, and depot formulations of antipsychotic drugs, should be avoided.

References (4)
  1. (2002) "Product Information. Chloromycetin (chloramphenicol)." Parke-Davis
  2. (2022) "Product Information. Chloromycetin (chloramphenicol)." Pfizer Canada Inc
  3. (2015) "Product Information. Chloromycetin Succinate (chloramphenicol)." Link Medical Products Pty Ltd T/A Link Pharmaceuticals
  4. (2023) "Product Information. Chloramphenicol (chloramphenicol)." Eramol (UK) Ltd

Drug and food interactions

Moderate

levamisole food

Applies to: Ergamisol (levamisole)

GENERALLY AVOID: Case histories have suggested that levamisole is associated with some side effects (including headache, fever, shivers, and dizziness) that suggest an disulfiram-like interaction with alcohol. These side effects could be alleviated by total abstinence from alcohol. No mechanism has been established for this interaction.

MANAGEMENT: Patients receiving levamisole should avoid alcohol.

References (3)
  1. (2001) "Product Information. Ergamisol (levamisole)." Janssen Pharmaceuticals
  2. Renoux G (1980) "The general immunopharmacology of levamisole." Drugs, 19, p. 89-99
  3. Renoux G (1978) "Modulation of immunity by levamisole." Pharmacol Ther [B], 2, p. 397-422

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer